A
Alcista
Alcista · 25%VRDN
$17.31
Precio del escenario
$19.030
-0.516 (-2.71%)Al cierre
Loading chart…
- Máximo
- 19.780
- Apertura
- 19.670
- Precio medio ponderado por volumen
- 19.25
- Volumen
- 2.46M
- Capitalización
- 815.65M
- Mínimo
- 18.940
- Importe
- 47.30M
- EV/EBITDA, TTM
- -0.02
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Análisis de IA of Viridian Therapeutics Inc (VRDN)
ComprarViridian Therapeutics Inc is a good buy right now due to its current price of $19.03, which is significantly lower than the analyst price target of $39, suggesting a potential upside of approximately 104%. Additionally, the company has a strong gross margin of 100%, indicating effective cost management despite recent losses. The main risk is the negative net income of -127,119,000 USD reported in Q2 2026, which highlights ongoing financial challenges that investors should monitor closely.
Métricas de valoración
El PER previsto actual de Viridian Therapeutics Inc (VRDN) es 1.01, frente a su media de 5 años de -4.20.
Escenarios de precio de Alphio AI para VRDN
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con VRDN en cartera
Cronología de eventos
Noticias
5.009-15Yahoo FinanceViridian Metals Flags Exploration Target of 41
2.007-14Yahoo FinanceMiddle East Conflict Impacts Oil Prices and Market Dynamics
5.006-30Yahoo FinanceViridian's Lumvoa Therapy for Thyroid Eye Disease Set to Launch
4.506-29NASDAQ.COMU.S. Stocks Close Higher, Led by Technology Gains
4.506-29NASDAQ.COMUS Stocks Rise, Led by Technology Sector Gains
Preguntas frecuentes sobre VRDN, respondidas por Alphio AI
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).
Viridian Therapeutics Inc is a good buy right now due to its current price of $19.03, which is significantly lower than the analyst price target of $39, suggesting a potential upside of approximately 104%. Additionally, the company has a strong gross margin of 100%, indicating effective cost management despite recent losses. The main risk is the negative net income of -127,119,000 USD reported in Q2 2026, which highlights ongoing financial challenges that investors should monitor closely.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.